MK-677 (Ibutamoren)
Also known as: Ibutamoren, Ibutamoren mesylate, MK-0677, MK0677, Ibutamoren Mesylate
Growth Hormone Secretagogue (GHS) / Ghrelin Receptor Agonist (non-peptide, orally active spiroindoline derivative)
What it is
MK-677 (ibutamoren) is an oral compound people take to raise growth hormone and IGF-1 levels for muscle preservation, fat loss, better sleep, and recovery from aging or illness. It works by mimicking ghrelin to trigger GH release from the pituitary. Not FDA-approved; banned by WADA; studied in clinical trials for sarcopenia and bone health.
The scientific side
MK-677 is an orally active, non-peptide spiroindoline derivative that acts as a potent agonist at the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor (PMID 36354265; PMID 28400207). It mimics the endogenous peptide ghrelin, binding to and activating GHS-R1a expressed predominantly in the brain, pituitary gland, and pancreas, as well as in peripheral tissues including the heart, adrenals, and gonads (PMID 15814848; PMID 11061542). Receptor activation stimulates pulsatile release of endogenous growth hormone (GH) through multiple mechanisms: increasing GHRH release, amplifying GHRH signaling in pituitary somatotrophs, reducing somatostatin release, and antagonizing somatostatin receptor signaling. GH release in turn stimulates hepatic and peripheral production of insulin-like growth factor-1 (IGF-1). Pharmacological studies demonstrate that MK-677 functions as an orthosteric agonist at GHS-R1a, competing directly with ghrelin for the same binding site at the interface of transmembrane domains III and VI, and displaying higher intrinsic efficacy than ghrelin itself in some assay systems (PMID 19625579; PMID 18923064; PMID 15905359). Unlike exogenous GH administration, GHS-mediated GH release remains subject to normal negative feedback, theoretically reducing the risk of supra-therapeutic GH levels.
Class: Growth Hormone Secretagogue (GHS) / Ghrelin Receptor Agonist (non-peptide, orally active spiroindoline derivative)
Administration & storage
- Administration
- Oral administration (capsule/tablet) — the only route reported in the reviewed human clinical abstracts (PMID: 18981485; PMID: 9467534; PMID: 21067829; PMID: 15066065; PMID: 11238495; PMID: 10404019)
- Storage
- No storage conditions for MK-677 are described in the reviewed abstracts.
- Cautions
- A clinical trial of MK-677 25 mg/day in elderly hip-fracture patients was terminated early due to a safety signal of congestive heart failure in a limited number of patients; MK-677 was described as having an unfavorable safety profile in this population.,MK-677 consistently increased fasting blood glucose and decreased insulin sensitivity in human RCTs; monitoring of glucose homeostasis is warranted (PMID: 18981485; PMID: 9467542).,A case report documents hepatotoxicity (transaminitis) in a man in his early 30s who consumed MK-677 for 2 months; liver function tests normalized after stopping the supplement.,At a dose of 3 mg/kg in transgenic mice (5xFAD), MK0677 significantly increased mortality; the clinical relevance of this finding is unknown.,MK-677 is found unlabeled in commercially available dietary supplements; products may contain undisclosed additional compounds including SARMs and undisclosed steroid hormones, representing a significant purity and contamination risk (PMID: 33934684; PMID: 39145153).,Use of sterile technique applies to any injectable compound; however, all reviewed clinical studies used oral administration only — injection of non-pharmaceutical-grade material carries unknown risks.
Legal & regulatory status
Not approved as a drug by the FDA for any indication per the reviewed literature. Reviewed literature notes strict FDA criteria for GH use and describes MK-677 as an investigational compound. Detected unlabeled in…
Listed on the World Anti-Doping Agency prohibited list. Described as a banned performance-enhancing drug.
Not stated in reviewed literature — requires manual verification
What it's studied for
- Sarcopenia / Preservation of fat-free mass in healthy older adults Human RCT
- In a 2-year double-blind RCT of 65 healthy older adults (60–81 years), daily oral MK-677 25 mg significantly increased GH and IGF-1 to young-adult levels, increased fat-free mass (+1.1 kg vs −0.5 kg placebo; P<0.001), and increased body cell mass. No significant change in abdominal visceral fat. Most frequent side effe PMID 18981485 Nass R et al. Ann Intern Med. 2008;149(9):601-611.
- In a 2-month RCT of 24 obese males, MK-677 25 mg/day significantly increased serum IGF-I (~40%), GH, and fat-free mass (by DXA and 4-compartment model). Basal metabolic rate transiently increased at 2 weeks. Oral glucose tolerance impaired at 2 and 8 weeks. No significant change in total or visceral fat. PMID 9467542 Svensson J et al. J Clin Endocrinol Metab. 1998;83(2):362-369.
- Reversal of diet-induced catabolism / nitrogen wasting Human RCT
- In a double-blind crossover RCT of 8 healthy male volunteers under caloric restriction, MK-677 25 mg orally once daily for 7 days significantly reversed diet-induced negative nitrogen balance (mean daily nitrogen balance +0.31 g/day vs −1.48 g/day placebo; P<0.01) and significantly increased IGF-I and IGFBP-3. Generall PMID 9467534 Murphy MG et al. J Clin Endocrinol Metab. 1998;83(2):320-325.
- Recovery from hip fracture in elderly Human RCT
- In a multicenter RCT of 161 elderly hip-fracture patients, oral MK-677 for 6 months increased serum IGF-I by 84% vs 17% on placebo. No statistically significant differences in functional performance measures or overall Sickness Impact Profile score. The trend toward improvement in several lower-extremity measures was n PMID 15066065 Bach MA et al. J Am Geriatr Soc. 2004;52(4):516-523.
- In a multicenter RCT of 123 elderly hip-fracture patients assigned to MK-677 25 mg/day or placebo, gait speed improved significantly (P=0.011) but most other functional measures did not. IGF-1 increased significantly. Trial terminated early due to a safety signal of congestive heart failure in a limited number of patie PMID 21067829 Adunsky A et al. Arch Gerontol Geriatr. 2011;53(2):183-192.
- Bone turnover / osteoporosis Human RCT
- In three randomized double-blind studies totaling 187 elderly adults, oral MK-677 (10 or 25 mg daily, 2–9 weeks) significantly increased markers of bone resorption (urinary NTx) and formation (osteocalcin, BSAP) and serum IGF-I levels (55–94% increase). Dose-response relationship observed. PMID 10404019 Murphy MG et al. J Bone Miner Res. 1999;14(7):1182-1188.
- In a multicenter 18-month RCT of 292 postmenopausal osteoporotic women, MK-677 25 mg ± alendronate 10 mg daily: MK-677 alone increased IGF-I by 39–45%, increased bone turnover markers, and in combination with alendronate increased femoral neck BMD by 4.2% vs 2.5% for alendronate alone (P<0.05). No enhancement in lumbar PMID 11238495 Murphy MG et al. J Clin Endocrinol Metab. 2001;86(3):1116-1125.
- In an 8-week RCT of 24 obese males, MK-677 25 mg/day significantly increased markers of bone formation (procollagen I carboxy-terminal propeptide +23%, procollagen III peptide +28%, osteocalcin +15%) and resorption (carboxy-terminal cross-linked telopeptide +26%). Also increased IGFBP-5 by 43–44%. PMID 9661080 Svensson J et al. J Bone Miner Res. 1998;13(7):1118-1126.
- Protein-energy wasting in end-stage renal disease / hemodialysis Human RCT
- In a randomized crossover double-blind study of 22 hemodialysis patients completing a 3-month crossover, MK-0677 (oral ghrelin receptor agonist) increased geometric mean IGF-1 by 1.76-fold (95% CI 1.48–2.10; P<0.001) compared with 1.07-fold on placebo. A 65% greater increase in IGF-1 vs placebo (95% CI 33–104%; P<0.001 PMID 28340044 Campbell GA et al. Nephrol Dial Transplant. 2018;33(3):523-530.
- Alzheimer's disease — slowing cognitive progression Human RCT
- In a double-blind multicenter RCT of 563 patients with mild-to-moderate AD randomized to MK-677 25 mg or placebo daily for 12 months, IGF-1 increased 60.1% at 6 weeks and 72.9% at 12 months. No significant differences on CIBIC-plus, ADAS-Cog, ADCS-ADL, or CDR-sob. MK-677 25 mg was ineffective at slowing AD progression. PMID 19015485 Sevigny JJ et al. Neurology. 2008;71(21):1702-1708.
- In 5xFAD transgenic mice treated with MK0677, neurogenesis was fostered but no prevention of hippocampal Aβ deposition, synaptic loss, microglial activation, or cognitive impairment was observed. MK0677 at 3 mg/kg significantly increased mouse mortality. Findings suggested ineffectiveness of MK0677 alone for AD prevent PMID 31594237 Tian J et al. J Alzheimers Dis. 2019;72(1):91-105.
- Effects on lipoproteins in obese subjects Human RCT
- In an 8-week RCT of 24 obese males, MK-677 25 mg/day reduced the LDL-C/HDL-C ratio at study end (P<0.05 vs placebo). Increases in apoA-I, apoE, HDL-C, and triglycerides were transient (resolved by 8 weeks). No significant change in Lp(a) or total/LDL cholesterol at end of study. PMID 10372705 Svensson J et al. J Clin Endocrinol Metab. 1999;84(6):2028-2033.
- GH isoform effects in obese subjects Human RCT
- In 12 obese males treated with MK-677 25 mg/day orally for 8 weeks, the proportion of non-22kDa GH isoforms was higher in peak GH samples after the initial dose than after 2 and 8 weeks (P<0.01 and P<0.05, respectively). The proportion of 20K GH in 2-hour samples after the initial dose was lower than after 2 and 8 week PMID 12550076 Svensson J et al. Growth Horm IGF Res. 2003;13(1):44-51.
- Body composition and leptin/thyroid effects in obese subjects Human RCT
- In an 8-week RCT of 24 healthy obese males, MK-677 25 mg/day transiently increased serum leptin and leptin/body fat ratio at 2 weeks (P<0.05 vs placebo). Free T3 increased at 8 weeks (P<0.05 vs placebo). Peak TSH concentration increased at 8 weeks but remained within normal range. Total testosterone reduced (P<0.05 vs PMID 10468903 Svensson J et al. Clin Endocrinol. 1999;51(3):321-326.
- Detection in anti-doping / hair testing contexts Human observational
- A single 10 mg dose of ibutamoren tested positive in hair at 1.3 pg/mg (0–1 cm segment) in a male volunteer collected 4 weeks post-exposure. After consumption of 60 capsules at 10 mg over 90 days, the 0–4 cm hair segment tested positive at 224 pg/mg. LOD established at 0.1 pg/mg. First report establishing incorporation PMID 40882886 Kintz P, Gheddar L. Clin Chim Acta. 2026.
- Following oral administration of MK-0677 mesylate to a Thoroughbred racehorse, MK-0677 and its O-dealkylated metabolite were detected in all collected hair samples up to 209 days in mane and 358 days in tail by LC-MS/MS. Wash procedures confirmed internal incorporation (via bloodstream) at later time points (≥52 days). PMID 36354265 Viljanto M et al. Drug Test Anal. 2023;15(2):208-219.
Safety signals
- Congestive heart failure: A Phase IIb RCT (n=123 elderly hip-fracture patients, MK-677 25 mg/day) was terminated early due to a safety signal of congestive heart failure in a limited number of patients. PMID 21067829
- Impaired glucose homeostasis / decreased insulin sensitivity: Consistently observed across multiple human RCTs with MK-677, including increased fasting blood glucose and impaired oral glucose tolerance. PMID 18981485
- Impaired glucose tolerance in obese males: Oral glucose tolerance test showed impairment at 2 and 8 weeks of MK-677 25 mg/day treatment. PMID 9467542
- Hepatotoxicity (transaminitis): Case report of a male in his early 30s who developed transaminitis after 2 months of MK-677 supplementation; normalized after cessation. PMID 40675653
- Increased appetite, transient lower-extremity edema, and muscle pain reported as the most frequent side effects in a 2-year RCT in healthy older adults. PMID 18981485
- Increased cortisol levels: Cortisol increased by 47 nmol/L (CI 28–71 nmol/L) in MK-677 recipients vs placebo in a 2-year RCT in older adults. PMID 18981485
- Reduced total testosterone: MK-677 25 mg/day for 8 weeks significantly reduced serum total testosterone in obese males (P<0.05 vs placebo). PMID 10468903
- Negative impact on bone, serum lipids (LDL +40%, triglycerides +39.2%), liver enzymes (ALT +205%, AST +95.8%), and total/free testosterone (total −62.3%, free −85.7%) observed in a case report of a 25-year-old male co-administering LGD-4033 (10 mg) and MK-677 (15 mg) daily for 5 weeks. Note: confounded by co-administration of LGD-4033. PMID 36303408
- Gynecomastia and hypogonadotropic hypogonadism: Case report in a 40-year-old male consuming supplements containing MK-677, RAD-140, and cardarine (plus undisclosed steroids). Causation cannot be attributed to MK-677 alone. PMID 39145153
- Increased mouse mortality at 3 mg/kg in 5xFAD transgenic mice. PMID 31594237
- GH-mediated adverse effects (not further specified) noted in groups receiving MK-677 in an 18-month osteoporosis RCT; adverse events resulting in discontinuation were relatively infrequent. PMID 11238495
Contraindications
- Diabetes mellitus: Patients with diabetes mellitus were explicitly excluded from the hip-fracture clinical trial, likely due to concerns about glucose homeostasis impairment associated with MK-677. PMID 15066065
- Congestive heart failure: Patients with congestive heart failure were excluded from the hip-fracture clinical trial; a safety signal of congestive heart failure was observed during the trial and led to early termination. PMID 21067829
- Cancer: Patients with cancer were excluded from the hip-fracture clinical trial. PMID 15066065
- Uncontrolled hypertension: Excluded from the hip-fracture clinical trial. PMID 15066065
Protocol
25 mg oral, once daily. Cycle: 8-12 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Oral | 25 mg once daily (oral) | Up to 2 years | human | Research PMID 18981485 |
| Oral | 25 mg once daily (oral) | 7 days (during caloric restriction) | human | Research PMID 9467534 |
| Oral | 25 mg once daily (oral) | 8 weeks | human | Research PMID 9467542 |
| Oral | 25 mg once daily (oral) | 8 weeks | human | Research PMID 12550076 |
| Oral | 25 mg once daily (oral) | 8 weeks | human | Research PMID 10468903 |
| Oral | 25 mg once daily (oral) | 8 weeks | human | Research PMID 10372705 |
| Oral | 25 mg once daily (oral) | 8 weeks | human | Research PMID 9661080 |
| Oral | 25 mg once daily (oral) | 12 months | human | Research PMID 19015485 |
| Oral | 25 mg once daily (oral) | 24 weeks | human | Research PMID 21067829 |
| Oral | Oral once daily for 6 months | 6 months | human | Research PMID 15066065 |
| Oral | 25 mg once daily (oral) | 18 months | human | Research PMID 11238495 |
| Oral | 10 mg or 25 mg once daily (oral); escalating dose protocols also used (5, 10, or 25 mg for initial 2 weeks then 25 mg; also 25 mg for 2 weeks then 50 mg for 2 weeks) | 2–9 weeks | human | Research PMID 10404019 |
| Oral | Oral ghrelin receptor agonist MK-0677 (specific dose not stated in abstract) | 3-month crossover | human | Research PMID 28340044 |
| Oral | 15 mg daily (oral), co-administered with LGD-4033 10 mg daily | 5 weeks | human | Research PMID 36303408 |
| Oral | Single dose 10 mg (oral); also 60 capsules × 10 mg over 90 days | Single dose or 90 days | human | Research PMID 40882886 |
| Not specified in abstract | 3 mg/kg | Not fully specified in abstract | animal | Research PMID 31594237 |
| oral | 10 mg | once daily, taken at night before bed · 8-16 weeks | biohackers and fitness enthusiasts seeking GH pulse amplification and improved sleep quality | [Community] |
| oral | 25 mg | once daily, taken at night before bed · 8-16 weeks | intermediate-to-advanced biohackers, bodybuilders, and fitness athletes seeking muscle gain and fat loss | [Community] |
| oral | 12.5 mg | once daily, taken at night before bed · 8-16 weeks | beginners or individuals sensitive to hunger and water retention side effects | [Community] |
| oral | 25 mg | once daily · 6 months to 1 year (long-term / continuous use) | anti-aging biohackers and longevity-focused adults over 35 | [Community] |
| oral | 50 mg | once daily, taken at night · 8-12 weeks | advanced bodybuilders seeking maximum GH/IGF-1 stimulus during a bulk phase | [Community] |
| oral | 25 mg | once daily · 8-12 weeks | post-cycle therapy (PCT) users seeking to maintain IGF-1 levels after anabolic steroid cycles | [Community] |
| oral | 10 mg | once daily, taken at night · 12-24 weeks | adults over 40 focused on longevity, GH restoration, and sleep quality rather than muscle gain | [Community] |
| oral | 25 mg | once daily · 8-12 weeks | athletes and fitness users stacking MK-677 with SARMs (e.g., LGD-4033, RAD-140, Ostarine) for body recomposition | [Community] |
| oral | 25 mg | 5 days on / 2 days off · 12-16 weeks | biohackers attempting to mitigate hunger and metabolic side effects while maintaining GH stimulus | [Community] |
| oral | 10-25 mg | once daily, taken in the morning · 8-12 weeks | users who experience excessive vivid dreams or sleep disruption with nighttime dosing | [Community] |
All studies (26)
- PMID 9467534 Human RCT
Reversal of diet-induced catabolism / nitrogen wasting - PMID 9467542 Human RCT
Sarcopenia / Preservation of fat-free mass in healthy older adults - PMID 9661080 Human RCT
Bone turnover / osteoporosis - PMID 10372705 Human RCT
Effects on lipoproteins in obese subjects - PMID 10404019 Human RCT
Bone turnover / osteoporosis - PMID 10468903 Human RCT
Body composition and leptin/thyroid effects in obese subjects - PMID 11238495 Human RCT
Bone turnover / osteoporosis - PMID 12550076 Human RCT
GH isoform effects in obese subjects - PMID 15066065 Human RCT
Recovery from hip fracture in elderly - PMID 18981485 Human RCT
Sarcopenia / Preservation of fat-free mass in healthy older adults - PMID 19015485 Human RCT
Alzheimer's disease — slowing cognitive progression - PMID 21067829 Human RCT
Recovery from hip fracture in elderly - PMID 28340044 Human RCT
Protein-energy wasting in end-stage renal disease / hemodialysis - PMID 31594237 Human RCT
Alzheimer's disease — slowing cognitive progression - PMID 36354265 Human observational
Detection in anti-doping / hair testing contexts - PMID 40882886 Human observational
Detection in anti-doping / hair testing contexts - PMID 11061542
- PMID 15814848
- PMID 15905359
- PMID 18923064
- PMID 19625579
- PMID 28400207
- PMID 33934684
- PMID 36303408
15 mg daily (oral), co-administered with LGD-4033 10 mg daily Oral (human) - PMID 39145153
Gynecomastia and hypogonadotropic hypogonadism: Case report in a 40-year-old male consuming supplements containing MK-677, RAD-140, and cardarine (plus undisclo - PMID 40675653
Hepatotoxicity (transaminitis): Case report of a male in his early 30s who developed transaminitis after 2 months of MK-677 supplementation; normalized after ce